Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

UPDATE: Legend Discloses Carvykti's Q2 2022 Revenue of $24M

Here is a brief preview of this blast: On Thursday, July 21, Legend Biotech reported (6-K SEC) that Carvykti (JNJ / Legend’s BCMA CAR-T) generated approximately $24M in "net trade sales" in Q2 2022. Of note, during JNJ's Q2 2022 earnings call, management highlighted that the first Carvykti sales had been recorded, but did not disclose its Q2 2022 revenue (see previous insight). The Celltelligence team will analyze how Carvykti's revenue compares with key competitor Abecma (BMS's BCMA CAR-T) after BMS releases its Q2 2022 financial results on July 27, 2022.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.